Aevisbio

AevisBio is a clinical-stage biopharmaceutical company focused on developing next-generation immunomodulatory imide drug (IMiD)-based therapeutics for neurological and neuroinflammatory diseases. The company leverages targeted protein degradation technology derived from IMiD-cereblon interactions to develop novel small-molecule treatments for conditions including Alzheimer's disease, ischemic stroke, and other neurodegenerative disorders. AevisBio has a dual presence with operations in Daejeon, Republic of Korea and Gaithersburg, Maryland, USA. Its lead pipeline candidates AEV-103 and AEV-003 are advancing through IND-enabling studies in collaboration with the U.S. National Institutes of Health (NIH).